Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 7/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.30 |
| ▸ | RAF1 | P04049 | 2/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | GPR6 | P46095 | 1/20 | 0.30 |
| ▸ | CFTR | P13569 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24988224 | 0.93 | GABRA5 (0.32) | GABRA5PIK3CACFTR | |
| SCHEMBL24987242 | 0.93 | GABRA5 (0.32) | GABRA5PIK3CACFTR | |
| SCHEMBL23905251 | 0.93 | GABRA5 (0.32) | GABRA5PIK3CACFTR | |
| SCHEMBL23905489 | 0.93 | GABRA5 (0.33) | GABRA5 | |
| SCHEMBL24988033 | 0.92 | GABRA5 (0.35) | GABRA5PTGS1PTGS2ALOX5CFTR | |
| SCHEMBL26527274 | 0.92 | GABRA5 (0.32) | GABRA5PIK3CARAF1BRAFCFTR | |
| SCHEMBL24986028 | 0.92 | CFTR (0.32) | GABRA5CFTR | |
| SCHEMBL24986036 | 0.92 | CFTR (0.32) | GABRA5CFTR | |
| SCHEMBL25115607 | 0.91 | GABRA5 (0.32) | GABRA5PIK3CA | |
| SCHEMBL25117147 | 0.91 | GABRA5 (0.32) | GABRA5PIK3CACFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572367-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | GABRA5 3773/4885SSTR5 1379/4885PIK3CA 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.